Navigation Links
Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
Date:3/23/2009

NEW BRUNSWICK, N.J., March 23 /PRNewswire/ -- Each year in the United States more than 138,000 people are diagnosed with leukemia, lymphoma or myeloma. These new cases account for 10 percent of the new total cancer cases in the U.S. per year. For several types of leukemia, the survival rate has not changed in the past 25 years.

That's why James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, is proud to announce that the company has made a $500,000 commitment to Actinobac Biomed Inc., a company developing a therapeutic agent targeting white leukemic blood cells for the treatment of hematological malignancies, including leukemia, myeloma and lymphoma.

"Based on current statistics, one can see there is a great need to introduce new therapies for patients suffering from hematologic malignancies," explained Dr. Scott Kachlany. "Our primary drug candidate, Leukotoxin, has shown significant success in laboratory and animal studies. With this investment from Foundation Venture Capital Group we look toward moving our research further at a more rapid pace."

Dr. Kachlany, founder of Actinobac Biomed and an associate professor of oral biology, microbiology and molecular genetics at UMDNJ-New Jersey Dental School, discovered the agent, Leukotoxin, during the course of his research at the dental school.

The research was originally funded with one-year matching grants from the New Jersey Commission on Science and Technology and the Foundation of UMDNJ Annual Program Committee Awards.

Leukotoxin is a bacterial toxin that targets while blood cells. In laboratory studies, malignant white blood cells have been determined to be more sensitive to Leukotoxin than non-cancerous white blood cells. Animal studies in Dr. Kachlany's lab using mouse models for human leukemia have shown Leukotoxin to possess significant anti-leukemia activity. The company is also looking at Leukotoxin for use in autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, lupus, Crohn's disease and ulcerative colitis.

"While there are numerous drug candidates under development for treating various forms of leukemia, Dr. Kachlany's approach to utilizing Leukotoxin is one that we think could have significant benefits," explained George F. Heinrich, M.D., vice chair and CEO of Foundation Venture Capital Group.

Foundation Venture Capital Group was founded in 2006 to invest only in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey. Since that time it has invested in three other UMDNJ companies including Longevica Pharmaceuticals, Inc. which is developing a chemoprotective agent that may keep normal cells healthy during cancer treatments; CellXplore, Inc., a company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer and Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.

For more information, contact James Golubieski, president of Foundation Venture Capital Group, at (732) 235-5400 or at jgolubieski@njhf.org.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. The Oral Cancer Foundation Urges HPV Vaccination for Males
6. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
7. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
8. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
9. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
10. Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1
11. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)...  A recent study at Shriners Hospitals for Children ... the country dedicated to the treatment of pediatric burns ... the Surfacide Helios ® UV-C Disinfection System is ... pathogens not killed by the EVS (manual) cleaning process ... Burn Association,s 49th Annual Meeting in Boston ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ... to offer shares of common stock in an underwritten ... file with the Securities and Exchange Commission (the "SEC"). ... and there can be no assurance as to whether ... to the actual size or terms of the offering. ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... Georgia (PRWEB) , ... March 27, 2017 , ... ... to announce that for a second year in a row; they are the ... healthcare designers in the industry voted on the award at Design Connections 2017. ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center will ... April 3rd to commemorate the two-year anniversary of the facility. The event will ... two great years while also familiarizing themselves with the facility. , In the ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
Breaking Medicine News(10 mins):